Valsartan and the renin-angiotensin-aldosterone system: Blood pressure control and beyond

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 1, Issue SUPPL. 2, 2000, Pages 14-16

  Dahlöf, Björn ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiotensin II receptor blocker; Organ damage; Reversal of left ventricular hypertrophy; Valsartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE; VALSARTAN;

BLOOD PRESSURE; BLOOD VESSEL; DRUG EFFECT; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; KIDNEY DISEASE; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; BLOOD VESSELS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY DISEASES; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; VALINE;

EID: 0347308025     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2000.047     Document Type: Article

References (22)

1. 1999 World Health Organisation-International Society of Hypertension Guidelines for the management of hypertension. J Hypertens 1999; 17: 151-83.
2. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000; 283:1957-75.
3. Dahlöf B, Hansson L, Lindholm L et al. STOP-Hypertension: Swedish Trial in Old Patients with Hypertension. J Hypertens 1986; 4: 511-3.
4. Lever AF, Beevers DG, Hole DJ et al. Mortality amongst patients of the Glasgow Blood Pressure Clinic was high in the 1970s and 80s but has fallen since, why? Clin Exp Hypertens 1999; 21: 553-62.
5. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 2000; 342: 145-153.
6. Dahlöf B, Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy. Blood Press Suppl 1994; 2: 35-40.
7. Wing LM, Reid CM, Ryan P et al. Second Australian National Blood Pressure Study (ANBP2). Australian Comparative Outcome Trial of ACE inhibitor-and diuretic-based treatment of hypertension in the elderly. Management Committee on behalf of the High Blood Pressure Research Council of Australia. Clin Exp Hypertens 1997; 19: 779-91.
8. Schmieder RE, Schlaich MP. 1998 Comparison of therapeutic studies on regression of left ventricular hypertrophy. Adv Exp Med Biol 1997; 432: 191-8.
9. Yalcin F, Aksoy FG, Muderrisoglu H et al. Treatment of hypertension with perindopril reduces plasma atrial natriuretic peptide levels, left ventricular mass, and improves echocardiographic parameters of diastolic function. Clin Cardiol 2000; 23: 437-41.
10. Kjeldsen SE, Dahlof B, Devereux RB et al. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. Am J Hypertens 2000; 8 :899-906.
11. Devereux RB, Roman MJ, Palmieri V et al. Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension. J Hypertens 2000; 8:1129-38.
12. Thurmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98:2037-42.
13. Wachtell K, Palmieri V, Olsen MH et al. Parallel cardiac and renal end-organ damage in hypertensive patients with electrocardiographic left ventricular hypertrophy. The LIFE Study. (Submitted).
14. Muirhead N, Feagan BF, Mahon J. The effects of valsartan and capropril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial. Current Therapeutic Res 2000; 60:650-60.
15. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000;101:1653-9.
16. Black HR, Graff A, Shute D et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens 1997;11:483-9.
17. Corea L, Cardoni O, Fogari R et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996;60:341-6.
18. Langtry HD, McClellan KJ. Valsartan/hydrochlorothiazide. Drugs 1999;57:751-5; discussion 756-8.
19. Bodin F. Pharmacological and clinical profile of valsartan. J Hypertens 2000;18:S1-S7.
20. Mann J, Julius S.The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure 1998;7:176-83.
21. Cohn JN. Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in Heart Failure Trial. Cardiology 1999;91(Suppl 1):19-22.
22. Pfeffer MA, McMurray J, Leizorovicz A et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000;140:727-50.